Compare ESPR & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | QNST |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 694.8M |
| IPO Year | 2013 | 2009 |
| Metric | ESPR | QNST |
|---|---|---|
| Price | $3.13 | $11.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.75 | ★ $24.75 |
| AVG Volume (30 Days) | ★ 9.9M | 916.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | ★ $403,135,000.00 | $282,140,000.00 |
| Revenue This Year | N/A | $18.59 |
| Revenue Next Year | $12.81 | $14.80 |
| P/E Ratio | ★ N/A | $11.08 |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.95 | $10.29 |
| 52 Week High | $4.18 | $17.13 |
| Indicator | ESPR | QNST |
|---|---|---|
| Relative Strength Index (RSI) | 69.52 | 46.86 |
| Support Level | $3.11 | $11.57 |
| Resistance Level | $3.18 | $12.62 |
| Average True Range (ATR) | 0.01 | 0.49 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 75.00 | 54.18 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.